UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Mark One
For the quarterly period ended
For the transition period from to
Commission File No.
(Exact name of registrant as specified in its charter)
| 7374 |
| ||
(State or Other Jurisdiction of |
| (Primary Standard Industrial |
| (IRS Employer |
Incorporation or Organization) |
| Classification Number) |
| Identification Number) |
(Address of principal executive offices)
Registrant’s telephone number, including area code: (
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
| None |
| None |
Securities registered pursuant to Section 12(g) of the Act: Common stock, par value $0.0001
Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Accelerated Filer ☐ |
Smaller reporting company | |
Emerging growth company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the practicable date:
Class |
| Outstanding as of November 12, 2026 |
Common Stock: $0.0001 par value |
|
TABLE OF CONTENTS
|
| |||
Item 1. |
|
| 3 | |
|
|
| 4 | |
|
|
| 5 | |
|
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (unaudited) |
| 6 |
|
|
| 7 | |
|
|
| 8 | |
Item 2. |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations |
| 14 |
Item 3. |
|
| 21 | |
Item 4. |
|
| 21 | |
|
|
|
|
|
|
| |||
Item 1. |
|
| 22 | |
Item 1A. |
|
| 22 | |
Item 2. |
|
| 22 | |
Item 3. |
|
| 22 | |
Item 4. |
|
| 22 | |
Item 5. |
|
| 22 | |
Item 6. |
|
| 23 | |
|
|
| 24 | |
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. These financial statements should be read in conjunction with the Company’s December 31, 2025 audited financial statements and notes thereto. Operating results for the nine months ended September 30, 2026 are not necessarily indicative of the results that can be expected for the year ending December 31, 2026.
3
BIOSCIENCE HEALTH INNOVATIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, |
| December 31, |
2026 |
| 2025 | |
| (Unaudited) |
|
|
ASSETS |
|
|
|
Current Assets |
|
|
|
Cash and cash equivalents | $ |
| $ |
Accounts receivable, net |
| ||
Income tax receivable |
| ||
Operating digital assets |
| ||
Inventory |
| ||
Prepaid expense |
| ||
Overpayment to related parties |
| ||
Deferred tax asset |
| ||
Total current assets |
| ||
Other Assets |
|
|
|
Intangible assets |
| ||
Deposits |
| ||
Right -of-use asset |
| ||
Total other assets |
| ||
|
|
|
|
Total Assets | $ |
| $ |
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) |
|
|
|
Current Liabilities |
|
|
|
Accounts payable | $ |
| $ |
Accrued expenses |
| ||
Income tax payable |
| ||
Deferred revenue |
| ||
Related party advances |
| ||
Insurance loan |
| ||
Note payable - related party |
| ||
Total current liabilities |
| ||
|
|
|
|
STOCKHOLDERS' EQUITY (DEFICIT) |
|
|
|
Preferred stock: $0.0001 par value, 5,000,000 shares authorized; | - |
| - |
Series A Convertible Preferred Stock, |
| ||
Common stock: $ |
| ||
Additional paid-in capital |
| ||
Accumulated earnings (deficit) | ( |
| |
Total stockholders' equity (deficit) |
| ||
Total Liabilities and Stockholders' Equity (Deficit) | $ |
| $ |
See accompanying notes to the unaudited condensed consolidated financial statements.
4
BIOSCIENCE HEALTH INNOVATIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
| For the Three Months Ended |
| For the Nine Months Ended | ||||
|
| September 30, |
| September 30, | ||||
| 2026 |
| 2025 |
| 2026 |
| 2025 | |
|
|
|
|
|
|
|
|
|
Revenues |
| $ |
| $ |
| $ |
| $ |
Cost of goods sold |
| ( |
| ( |
| ( |
| ( |
Gross Profit |
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
Operating Expenses: |
|
|
|
|
|
|
|
|
General and administrative expenses |
|
|
|
| ||||
Consulting fees |
|
|
|
| ||||
Total Operating Expenses |
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
Income (Loss) from Operations |
| ( |
| ( |
| ( |
| |
|
|
|
|
|
|
|
|
|
Other Expense: |
|
|
|
|
|
|
|
|
Interest expense |
|
|
|
| ||||
Total Other Expense |
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
Loss before income taxes |
| ( |
| ( |
| ( |
| |
Income tax expense |
|
|
| ( |
| |||
|
|
|
|
|
|
|
|
|
Net Income (Loss) |
| $( |
| $( |
| $( |
| $ |
|
|
|
|
|
|
|
|
|
Net income (loss) per common share - basic |
| $( |
| $( |
| $( |
| $ |
Net income (loss) per common share - diluted |
| $( |
| $( |
| $( |
| $ |
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding – basic |
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding – diluted |
|
|
|
| ||||
See accompanying notes to the unaudited condensed consolidated financial statements.
5
BIOSCIENCE HEALTH INNOVATIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(Unaudited)
| Series A Convertible |
|
|
|
|
| Additional |
|
|
|
| ||
| Preferred Stock |
| Common Stock |
| Paid-in |
| Accumulated |
|
| ||||
| Shares |
| Amount |
| Shares |
| Amount |
| Capital |
| Earnings (Deficit) |
| Total |
Balance at December 31, 2024 |
| $ |
|
| $ |
| $ |
| $( |
| $ | ||
Net income |
|
|
|
|
|
| |||||||
Balance at March 31, 2025 |
|
|
|
|
|
| |||||||
Net income |
|
|
|
|
|
| |||||||
Balance at June 30, 2025 |
|
|
|
|
|
| |||||||
Net loss |
|
|
|
|
| ( |
| ( | |||||
Balance at September 30, 2025 |
| $ |
|
| $ |
| $ |
| $ |
| $ | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2025 |
| $ |
|
| $ |
| $ |
| $ |
| $ | ||
Common shares issued for cash |
|
|
|
|
|
| |||||||
Net loss |
|
|
|
|
| ( |
| ( | |||||
Balance at March 31, 2026 |
|
|
|
|
|
| |||||||
Common shares issued for cash |
|
|
|
|
|
| |||||||
Net loss |
|
|
|
|
| ( |
| ( | |||||
Balance at June 30, 2026 |
|
|
|
|
| ( |
| ||||||
Common shares issued for cash |
|
|
|
|
|
| |||||||
Net loss |
|
|
|
|
| ( |
| ( | |||||
Balance at September 30, 2026 |
| $ |
|
| $ |
| $ |
| $( |
| $ | ||
See accompanying notes to the unaudited condensed consolidated financial statements.
6
BIOSCIENCE HEALTH INNOVATIONS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| For the Nine Months Ended | ||
| September 30, | ||
| 2026 |
| 2025 |
|
|
|
|
Cash Flows From Operating Activities |
|
|
|
Net Income (Loss) | $( |
| $ |
Adjustments to reconcile net loss to net cash used in |
|
|
|
operating activities |
|
|
|
Lease cost, net of repayments |
| ||
Operating expenses paid with digital assets |
| ||
Changes in operating assets and liabilities: |
|
|
|
Accounts receivable | ( |
| |
Income tax receivable | ( |
| |
Inventory | ( |
| ( |
Digital assets | ( |
| |
Deferred revenue | ( |
| |
Deferred tax |
| ||
Accrued interest |
| ||
Accrued expenses |
| ||
Accounts payable |
| ||
Income tax payable | ( |
| |
Prepaid expenses | ( |
| ( |
Net Cash Provided by (Used in) Operating Activities | ( |
| |
|
|
|
|
Cash Flows From Investing Activities |
|
|
|
Purchase of intangible assets | ( |
| ( |
Net Cash Used in Investing Activities | ( |
| ( |
|
|
|
|
Cash Flows From Financing Activities |
|
|
|
Advances from related parties |
| ||
Repayment of related party advances | ( |
| ( |
Repayment of related party note payable | ( |
| |
Advanced from insurance loan |
| ||
Repayments to insurance loan | ( |
| |
Proceeds from the sale of common stock |
| ||
Net Cash Provided by Financing Activities |
| ||
|
|
|
|
Net Increase in Cash |
| ||
Cash at Beginning of Period |
| ||
Cash at End of Period | $ |
| $ |
|
|
|
|
Supplemental Cash Flow Information: |
|
|
|
Cash paid for interest | $ |
| $ |
Cash paid for income taxes | $ |
| $ |
|
|
| |
Conversion of related party advances to related party note payable | $ |
| $ |
Purchase of inventory with digital assets | $ |
| $ |
See accompanying notes to the unaudited condensed consolidated financial statements.
7
BIOSCIENCE HEALTH INNOVATIONS INC (FORMALY KNOWN AS NOWTRANSIT INC.)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026
(Unaudited)
Note 1 - Nature of Organization
Nowtransit Inc. (the “Company,” “us,” “we,” “Nowtransit”) was incorporated in the State of Nevada on July 8, 2019, and changed its name to BioScience Health Innovations Inc on February 21, 2025. Through March 10, 2023 we had no operations and had not generated any material revenues since inception. Effective March 10, 2023, we closed on a Share Exchange Agreement with Best 365 Labs Inc. (“Best”), a Nevada corporation, wherein we acquired all of the shares of Best and Best became a wholly owned subsidiary of the Company.
Best was incorporated on October 12, 2021 in the State of Nevada. Best sells clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels in the health and wellness market.
Note 2 - Liquidity
The condensed consolidated financial statements have been prepared in accordance with US generally accepted accounting principles, which assumes that the Company’s management will evaluate whether it will be able to meet its obligations and continue its operations in the normal course of business.
The Company had net income of $
Note 3 - Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and with the rules and regulations of the Securities and Exchange Commission, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements and should be read in conjunction with our audited financial statements. The financial statements are presented in US dollars, and the Company has adopted a December 31 year end.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates.
Segment Reporting
The Company operates as a single operating and reportable segment as a retailer selling mental health and general wellness products. Our Chief Executive Officer, who serves as our Chief Operating Decision Maker (“CODM”), evaluates the Company’s financial performance and makes resource allocation decisions considering our one geographical area and on a consolidated basis. Accordingly, the CODM considers the revenue, operating expenses, and other income (expenses) of our single operating segment as reported on the statement of operations and considers our current and total assets as recorded on the balance sheet. There are no additional expense or asset information that are supplemental to those disclosed in these condensed consolidated financial statements that are regularly provided to the CODM.
Cash and Cash Equivalents
Cash and cash equivalents include cash on hand, cash in banks and any highly liquid investments with a maturity of three months or less to the extent the funds are not being held for investment purposes. As of September 30, 2026 and December 31, 2025, the Company had no cash equivalents.
The Company maintains four accounts at Wells Fargo Bank. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $
Accounts Receivable and Allowance for Doubtful Accounts
The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company records an allowance for doubtful accounts that is based on historical trends, customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management’s estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to collect a receivable have failed. As of September 30, 2026 and December 31, 2025, the allowance for doubtful accounts was $
8
Inventory
The Company’s inventory is recognized in accordance with Accounting Standards Codification (“ASC”) 303. The Company uses the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of September 30, 2026 and December 31, 2025, the Company had $
Income Taxes
The provision for income taxes and deferred income taxes is determined using the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered, a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected to be realized.
Revenue Recognition
The Company’s revenue is recognized in accordance with Accounting Standards Codification 606 and the Company sells products in the immune health supplement market. The Company’s performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers that are end users of the Company’s products will generally remit payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred revenue. Customers that are resellers of the Company’s products are offered credit terms and generally pay within 30-60 days. As of September 30, 2026 and December 31, 2025 deferred revenue was $
Advertising Costs
Advertising costs are expensed as incurred. During the nine months ended September 30, 2026 and 2025, the Company incurred advertising costs of $
Research and Development
The Company charges research and development costs to expense when incurred. During the nine months ended September 30, 2026 and 2025, the Company incurred $
Intangible Assets
The Company accounts for its intangible assets in accordance with ASC 350. Costs incurred to renew or extend the term of intangible assets are expensed as incurred.
|
| Estimated Useful Life (years) |
| September 30, 2026 |
| December 31, 2025 |
Patents |
| $ | $ | |||
Software |
|
|
| |||
|
|
|
| |
| |
Accumulated amortization |
|
|
| |
| |
Net book value |
|
| $ | | $ | |
During the nine months ended September 30, 2026 and 2025 no amortization expense was recorded as the patents were still pending. The patent costs will be amortized on a straight-line basis over its estimated useful life once the patents are granted. Software will begin amortization in October 2026 as the Company did not start using the software till the end of the quarter. The software is a closed loop AI system that the Company will utilize in interacting with customers and analysing Company data. Amortization expense of $885 is expected for the year ended December 31, 2026 and $9,400 for each year ended December 31, 2027 and beyond.
We have several patent applications pending in the U.S. and internationally for our innovative methylithioninium (methylene blue) and mitochondrial health compositions:
Patent Pending Product Overview and Update
U.S. Non-Provisional Patent Application No. 18/931,277 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024
International Patent Application No. PCT/US24/53487 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024
U.S. Non-Provisional Patent Application No. 18/931,346 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024
International Patent Application No. PCT/US24/53490 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024. Filed on 10/30/2024
U.S. Provisional Patent Application No. 19/371,824 for TREATMENTS USING METHYLTHIONINIUM SALT, LIQUID MINERAL BLENDS, and/or SECONDARY PHYSIOLOGICALLY ACTIVE COMPOUND AND PHYSIOLOGICAL THERAPY, filed on 10/28/2025
9
U.S. Provisional Patent Application No. 63/712,895 for TREATMENTS USING METHYLTHIONINIUM SALT, SECONDARY PHYSIOLOGICALLY ACTIVE COMPOUND AND PHYSIOLOGICAL THERAPY, filed on 10/28/2024
U.S. Provisional Patent Application No. 63/754,434 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS, filed on 2/5/2025
U.S. Provisional Patent Application No. 19/173,875 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS, filed on 4/9/2025
International Patent Application No. PCT/US26/13809 for NUTRITIONAL SUPPLEMENT COMPOSITIONS AND METHODS FOR ENHANCING BIOLOGICAL FUNCTIONS, filed on 2/4/2026
U.S. Provisional Patent Application No. 64/025,742 for AQUEOUS PEPTIDE DELIVERY COMPOSITIONS AND METHODS, filed on 4/2/2026
All provisional applications were filed with the U.S. Patent and Trademark Office by Thorpe North and Western.
We believe these filings cover multiple potential patents and product opportunities. Leadership is actively exploring partnerships and strategic alliances to maximize value for stakeholders.
All products and methods described remain patent pending as of the date of this filing.
Impairment of Long-lived Assets
The Company applies the provisions of ASC 360, where applicable, to all long-lived assets and periodically evaluates the carrying value of long-lived assets to be held and used for impairment. Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in the results of operations. During the nine months ended September 30, 2026 and 2025, the Company recorded no impairment expense for their long-lived assets.
Digital Assets Held for Operational Purposes
The Company holds certain digital assets (primarily USDT) exclusively as a medium of exchange to facilitate inventory procurement from international vendors. Digital assets held for operational purposes are classified as current assets on the Consolidated Balance Sheets based on the Company’s intent and ability to utilize these assets within its normal operating cycle. The Company measures digital assets at fair value with changes recognized in other income (expense) in the Consolidated Statement of Operations. The Company tracks its cost basis of digital assets by-wallet in accordance with the first-in-first-out (“FIFO”) method of accounting.
Leases
The Company follows the provisions of ASC 842, and records right-of-use (“ROU”) assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company’s leases is not readily determinable, the Company’s applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments. The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option.
The Company has elected not to recognize ROU asset and lease obligations for its short-term leases, which are defined as leases with an initial term of 12 months or less.
On December 1, 2025, we entered a 15-month rental arrangement for our office and inventory space, at which time we paid for the lease in full with a single payment of $
Net Income (Loss) per Common Share
Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants. As of September 30, 2026 and 2025 there were dilutive securities of
Recent Accounting Pronouncements
The Company has reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements and has determined that there have been no standards that had, or will have, a material impact on its consolidated financial statements with exception to the following:
10
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires incremental disclosures about specific expense categories, including but not limited to, purchases of inventory, employee compensation, depreciation, amortization and selling expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted and the amendments may be applied either prospectively or retrospectively. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. The amendments only impact disclosures and are not expected to have an impact on the Company’s financial condition and results of operations.
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on our principal or, in the absence of a principal, most advantageous market for the specific asset or liability.
U.S. generally accepted accounting principles provide for a three-level hierarchy of inputs to valuation techniques used to measure fair value, defined as follows:
| Level 1: | Inputs that are quoted prices (unadjusted) for identical assets or liabilities in active markets that the entity can access. |
|
|
|
| Level 2: | Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability, including: |
| - | quoted prices for similar assets or liabilities in active markets; |
| - | quoted prices for identical or similar assets or liabilities in markets that are not active; |
| - | inputs other than quoted prices that are observable for the asset or liability; and |
| - | inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
| Level 3: | Inputs that are unobservable and reflect management’s own assumptions about the inputs market participants would use in pricing the asset or liability based on the best information available in the circumstances (e.g., internally derived assumptions surrounding the timing and amount of expected cash flows). |
Our financial instruments consist of cash, accounts receivable and accounts payable, and note payable. We have determined that the book value of our outstanding financial instruments as of June 30, 2026, and December 31, 2025, approximates the fair value due to their short-term nature or interest rates that approximate prevailing market rates.
Items recorded or measured at fair value on a recurring basis in the accompanying consolidated financial statements consisted of the following items as of September 30, 2026:
|
| Level 1 |
|
| Level 2 |
|
| Level 3 |
|
| Total |
| ||||
Operating digital assets (see Note 7) |
| $ |
|
| $ | - |
|
| $ | - |
|
| $ |
| ||
Total Assets |
| $ |
|
| $ | - |
|
| $ | - |
|
| $ |
| ||
Total Liabilities |
| $ |
|
| $ | - |
|
| $ | - |
|
| $ |
| ||
Note 4 - Related Party Transactions
During the nine months ended September 30, 2025 the Company received advances of $
During the nine months ended September 30, 2026 the Company purchased $
Note 5 – Insurance Loan
In May 2026 we received proceeds of $42,663 from a loan entered into to cover insurance premiums. Under the terms of the loan interest is to accrue at a rate of 7.95% per annum and instalment payments of $4,423 monthly began in June 2026. During the nine months ended September 30, 2026, we recorded $965 worth of interest on the loan. During the nine months ended September 30, 2026, we made principal and interest payments on the loan of $17,693.
Note 6 - Equity
Common Stock
The Company has
During the nine months ended September 30, 2026, the Company issued
11
On September 10, 2025, the Company filed a change in the articles of incorporation and increased the voting common stock from
During the nine months ended September 30, 2025, there were no issuances of common stock.
As of September 30, 2026 and December 31, 2025, the Company had
Preferred Stock
On October 19, 2021, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing up to
During the nine months ended September 30, 2026 and 2025 there were no issuances of preferred stock. As of September 30, 2026 and December 31, 2025, the Company had
Note 7 – Digital Assets
The Company accounts for digital assets in accordance with ASU 2023-08, which requires entities to measure crypto assets at fair value with changes recognized in the Statement of Operations each reporting period.
The following table presents the Company’s Digital Asset holdings as of September 30, 2026:
|
| Quantity |
| Cost Basis |
| Fair Value | ||||||
USDT |
|
|
|
| $ |
|
| $ |
| |||
Total digital assets held as of September 30, 2026 |
|
|
|
|
| $ |
|
| $ |
| ||
The following table presents a roll-forward of total digital assets for the nine months ended September 30, 2026, based on the fair value model under ASU 2023-08:
|
| Fair Value | ||
Balance as of December 31, 2025 |
| $ |
| |
Purchase of digital assets |
|
| |
|
Operating expenses paid with digital assets |
|
| ( |
|
Purchase of inventory with digital assets |
|
| ( |
|
Balance as of September 30, 2026 |
| $ |
| |
Note 8 - Subsequent Events
The Company has evaluated all events that occur after the balance sheet date through November 13, 2026, the date when the financial statements were available to be issued, to determine if they must be reported. Management of the Company determined that there are material subsequent events to be disclosed.
(A)Acquisition of Vital Core and Customer Relationship Platform
On November 5, 2026, the Company entered into a definitive agreement to acquire 100% of Vital Core, Inc. ("Vital Core"), which will operate as a wholly owned subsidiary of the Company upon closing. Vital Core develops hair-growth and scalp-care technologies utilizing proprietary formulations and Mods Max-enabled applications.
Separately, on November 5, 2026, the Company agreed to acquire a 40% ownership interest in an established customer relationship platform from Ageless Holdings, LLC ("Ageless Holdings"), a related party. The customer base consists of approximately 15,000 active peptide, health, and wellness customers. As consideration for the 40% interest, the Company agreed to issue 450,000 restricted shares of its common stock to Ageless Holdings. Solely for reference purposes based on the Company's $4.50 Regulation A offering price, the indicated transaction reference value is approximately $2,025,000; this negotiated benchmark does not represent the acquisition-date fair value to be recorded for financial reporting purposes. The Vital Core acquisition did not require the issuance of additional common shares. The related-party transaction will be documented and evaluated in accordance with the Company’s governance and SEC reporting requirements.
(B)Subsidiary Research Funding and Master Distribution Agreement
On November 6, 2026, the Company's subsidiary, Vital Core, entered into a Research Funding and Master Distributor Agreement with Rule Imports, LLC ("Rule Imports"). Under the terms of the agreement, Rule Imports committed to provide $250,000 in research and product development funding to Vital Core, payable in two equal installments of $125,000. The funding will support product development across Vital Core, Best365Labs, and other authorized Company product lines.
In addition, Vital Core appointed Rule Imports as a preferred, non-exclusive master distributor for covered product lines across its established sales channels in the peptide, health, and wellness markets. Rule Imports will receive research updates and ongoing access to research findings for product evaluation and commercial distribution planning.
12
The following is a pro forma consolidated balance sheet showing the balances after adjustments for the acquisition of the 40% ownership interest in the customer relationship platform and the receipt of funds from Rule Imports under Research Funding and Master Distributor Agreement.
BIOSCIENCE HEALTH INNOVATIONS, INC.
PRO FORMA PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEET
|
|
| (A) |
| (B) |
|
|
|
|
| Acquired Customer |
| Deferred |
| Pro Forma |
| September 30, |
| Relationship |
| Research |
| Following |
| 2026 |
| Platform |
| Funding |
| Transactions |
| (Unaudited) |
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
|
Cash and cash equivalents | $1,691,858 |
|
|
|
|
| $1,691,858 |
Restricted Cash |
|
|
|
| $250,000 |
| 250,000 |
Accounts receivable, net | 478,083 |
|
|
|
|
| 478,083 |
Income tax receivable | 34,992 |
|
|
|
|
| 34,992 |
Operating digital assets | 71 |
|
|
|
|
| 71 |
Inventory | 711,269 |
|
|
|
|
| 711,269 |
Prepaid expense | 91,378 |
|
|
|
|
| 91,378 |
Total current assets | 3,007,651 |
|
|
|
|
| 3,257,651 |
Other Assets |
|
|
|
|
|
|
|
Intangible assets | 170,307 |
| 2,025,000 |
|
|
| 2,195,307 |
Deposits | 4,400 |
|
|
|
|
| 4,400 |
Right -of-use asset | 21,870 |
|
|
|
|
| 21,870 |
Total other assets | 196,577 |
|
|
|
|
| 2,221,577 |
|
|
|
|
|
|
|
|
Total Assets | $3,204,228 |
| $2,025,000 |
| $250,000 |
| $5,479,228 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) |
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
|
Accounts payable | $38,653 |
|
|
|
|
| $38,653 |
Accrued expenses | 26,201 |
|
|
|
|
| 26,201 |
Deferred research funding |
|
|
|
| 250,000 |
| 250,000 |
Deferred revenue | 1,522 |
|
|
|
|
| 1,522 |
Related party advances | 8,803 |
|
|
|
|
| 8,803 |
Insurance loan | 25,935 |
|
|
|
|
| 25,935 |
Note payable - related party | 180,402 |
|
|
|
|
| 180,402 |
Total current liabilities | $281,516 |
|
|
| $250,000 |
| $531,515 |
|
|
|
|
|
|
|
|
STOCKHOLDERS' EQUITY (DEFICIT) |
|
|
|
|
|
|
|
Preferred stock: $0.0001 par value, 5,000,000 shares authorized; | - |
|
|
|
|
| - |
Series A Convertible Preferred Stock, 1,000,000 designated, | 14 |
|
|
|
|
| 14 |
Common stock: $0.0001 par value, 250,000,000 shares authorized; | 1,203 |
| 45 |
|
|
| 1,248 |
Additional paid-in capital, pro forma as adjusted | 3,185,373 |
| 2,024,955 |
|
|
| 5,210,328 |
Accumulated earnings (deficit) | (263,878) |
|
|
|
|
| (263,878) |
Total stockholders' equity (deficit) | 2,922,712 |
| 2,025,000 |
|
|
| 4,947,712 |
Total Liabilities and Stockholders' Equity (Deficit) | $3,204,228 |
| $2,025,000 |
| $250,000 |
| $5,479,228 |
Board Expansion in Connection with Planned Uplisting
Subsequent to September 30, 2026, BioScience Health Innovations Corp. (the “Company”) announced that two independent board member candidates, Mark Woodruff and Mark Thomas, have agreed to join the Company’s Board of Directors, with their appointments expected to become effective in connection with the Company's planned application to uplist to a senior U.S. securities exchange.
Mark Woodruff brings more than 30 years of experience in finance, investment management, and wealth advisory services. He earned a Bachelor of Science in Finance from the University of Utah in 1992 and an MBA from Brigham Young University in 1996. His professional background includes Fidelity Investments (1993–2000), Goldman Sachs (2000–2016), Alta Capital (2016–2022), and Physician Wealth Advisors (2022–present).
Mark Thomas brings more than 40 years of experience in business, sales, service, and construction, including 16 years in executive leadership. His background includes managing multimillion-dollar projects, overseeing budgets, revenue forecasting, and directing business operations. He also has an extensive history of community involvement throughout Utah.
The Company believes these prospective appointments will strengthen its corporate governance, financial oversight, and strategic leadership as it pursues a senior exchange listing. The planned appointments and potential uplisting remain subject to applicable corporate approvals, listing requirements, and other relevant conditions.
Engagement of Uplisting Advisor
Subsequent to the quarter ended September 30, 2026, BioScience Health Innovations Corp. (the “Company”) engaged Donohoe Advisory Associates LLC (www.donohoeadvisory.com) to provide strategic advisory services in connection with the Company’s pursuit of an uplisting of its common stock to a senior U.S. securities exchange. The engagement reflects the Company’s ongoing efforts to strengthen its capital markets position, enhance shareholder visibility, and pursue broader institutional investor access. There can be no assurance that the Company will satisfy applicable listing requirements or successfully complete an uplisting.
13
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Regarding Forward Looking Statements
This Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our discussions and the anticipated terms of a potential reverse merger pursuant to which we would acquire an operating business, our business plan and our liquidity needs. All statements other than statements of historical facts contained in this Report, including statements regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.
The results anticipated by any or all of these forward-looking statements might not occur. Important factors, uncertainties and risks that may cause actual results to differ materially from these forward-looking statements include those described elsewhere in this Report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under “Item 1A. – Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.
Recent Developments
Corporate Name Change
On February 21, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Formation with the Secretary of State of Nevada to change the Company’s corporate name to “BioScience Health Innovations Inc.”, with an effective date of February 21, 2025. The name change was approved by the Company’s Board of Directors on February 21, 2025.
Overview
As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting includes: Dementia and Alzheimer’s disease, ADHD and ADD, Long Covid, General Energy, Traumatic Brain Injury, Mild Cognitive Decline, GLP-1 Weight Loss, Sleep Improvement, Epilepsy and Seizure Reduction and Nasal Health and Allergy.
A trend that we believe is very beneficial and encouraging is the recent growing interest in mitochondria health and the role that mitochondria dysfunction plays in mental health and physical health issues. Methylene Blue and specialty natural options has emerged as valuable foundational health options on these fronts. We believe we are very well positioned and with adequate capital infusion we will be able to capitalize on multiple market opportunities.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Management’s discussion and analysis and results of operations are based upon our accompanying financial statements for the nine months ended September 30, 2026, which have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Note 3. Summary of Significant Accounting Policies, to the financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, describes the significant accounting policies and methods used in the preparation of the Company’s financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. These estimates are the basis for our judgments about the carrying values of assets and liabilities, which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under different assumptions or conditions.
Results Of Operations
THREE MONTHS ENDED SEPTEMBER 30, 2026 COMPARED TO SEPTEMBER 30, 2025
Our net loss for the three months ended September 30, 2026 was $149,225 compared to a net loss of $8,782 during the three months ended September 30, 2025. The Company has generated revenue of $970,071 and $1,131,427 during the three months ended September 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company also had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Expenses incurred were operating expenses of $785,824 during the three months ended September 30, 2026, compared to $707,013 during the three months ended September 30, 2025. Expenses increased as a result of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.
14
NINE MONTHS ENDED SEPTEMBER 30, 2026 COMPARED TO SEPTEMBER 30, 2025
Our net loss for the nine months ended September 30, 2026 was $564,885, compared to a net income $875,720 during the nine months ended September 30, 2025. The Company has generated revenue of $2,757,381 and $4,115,960 during the nine months ended September 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Operating expenses were $2,378,692 during the nine months ended September 30, 2026, compared to $1,793,134 during the nine months ended September 30, 2025. Expenses increased because of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.
LIQUIDITY AND CAPITAL RESOURCES
As of September 30, 2026, our total assets were $3,204,228, consisting of cash, accounts receivable, income tax receivable, digital assets, inventory, prepaid expenses, right-of-use assets, deposits, and intangible assets. The Company’s net working capital was $2,726,135 and management believes that its cash balance of $1,691,858 as of September 30, 2026 is sufficient to meet its obligations over the next year.
Cash Flows from Operating Activities
We have generated negative cash flows from operating activities. For the nine months ended September 30, 2026, net cash flows used in operating activities was $1,244,807, consisting of our net loss of $564,885 plus changes in operating activities of $679,922. For the nine months ended September 30, 2025, net cash flows providing in operating activities was $272,874, consisting of our net income of $875,720 offset by changes in operating activities of $602,846.
Cash Flows from Investing Activities
For the nine months ended September 30, 2026, we had net cash used in investing activities of $87,420 in connection with the purchase of intangible assets. For the nine months ended September 30, 2025, we had net cash used in investing activities of $46,064 in connection with the purchase of intangible assets.
Cash Flows from Financing Activities
For the nine months ended September 30, 2026, net cash flows provided by financing activities was $2,362,160, consisting of $756,923 in advances from related parties, advances from insurance loan of $42,663 and $2,010,267 of cash acquired for selling common stock, offset by repayments of related party advances of $150,000 and repayment of a related party note payable of $280,000 and repayments to insurance loan of $17,693. For the nine months ended September 30, 2025, net cash flows provided by financing activities was $250,096, consisting of advances from related parties of $2,422,096 offset by repayments to related parties of $2,172,000.
PLAN OF OPERATION AND FUNDING
The BioScience Health Innovations’ management team plans to focus on gaining traction for its mental health and general wellness products. Best 365 Labs, Inc has filed for a provisional patent on its mental wellness, natural products which is an additional reason we plan to focus and grow this sector of the products. With the Global Mental Health Marketplace currently valued at $383.31 billion annually and with 41 million people holding a prescription for Adderall that the market conditions are idea for us to offer our natural substitute product options (which are also unique).
As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in these potential marketplaces, through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting include:
15
ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
1. Executive Overview — Building a Cellular-Wellness and Delivery-Technology Platform
BioScience Health Innovations, Inc. (the “Company,” “BHIC,” “we” or “our”), through Best 365 Labs, is pursuing a business strategy built around differentiated consumer-health products and the potential commercialization of proprietary delivery technology. Management believes that MODS Max, a patent-pending stabilized aqueous mineral-oxide formulation system, represents a principal long-term strategic opportunity. The objective is to build both a commercially productive product portfolio and, subject to independent validation and market acceptance, a delivery platform that unrelated businesses may pay to incorporate or license.
Our “Ground Zero” cellular-wellness approach emphasizes products positioned around mitochondrial and foundational wellness. MODS Max is intended to serve as common formulation infrastructure across multiple compatible products, rather than a separate active ingredient. Management believes this model may provide additional sources of revenue beyond sales of individual products; those sources have not yet been established.
During 2026 management has devoted significant leadership attention and operating resources to supply-chain qualification, formulation and intellectual-property development, technical documentation, accounting infrastructure, and preparation for prospective strategic partners. These efforts have competed with time and resources available to near-term sales initiatives. Management considers this allocation a deliberate strategic priority, including in connection with its objective of improving readiness for a potential senior-exchange uplisting.
2. MODS Max — Our Core Strategic Technology
2.1 Technology and proposed mechanism
MODS Max is described in Company technical materials as a proprietary, stabilized aqueous mineral-oxide system intended for incorporation into selected sublingual, nasal and other formulations. Its value proposition relates to proprietary composition, processing, stabilization, formulation experience and possible effects on delivery of compatible active ingredients. Certain elements are the subject of pending patent applications; other details are maintained as confidential know-how. Patent applications do not assure patent issuance, breadth or enforceability.
The Company’s proposed technical hypothesis involves redox-associated interactions at biological interfaces and possible effects on epithelial transport. These mechanisms have not been established for MODS Max in controlled, independently reproducible human studies across the contemplated routes. No general absorption multiplier is asserted. Commercial use or formulation stability does not independently establish enhanced absorption.
2.2 Commercial deployment and operational validation
Company materials describe the incorporation of MODS Max into more than 30 formulations across cellular wellness, mitochondrial support, sleep, recovery and hormone-related product categories. Commercial liquid and nasal applications provide practical experience in formulation, manufacturing, product-specific stability, quality testing, distribution and customer adoption. Selected formulations have internal real-time stability observations extending beyond 12 months, subject to the tested products and conditions.
Management also considers its owned product lines and co-branded formulations important commercial reference applications for prospective third-party partners. Such experience constitutes operational and commercial deployment, not proof that MODS Max independently improves bioavailability or clinical outcomes. Independent route- and payload-specific studies remain necessary.
2.3 Routes and formats
Sublingual liquids | Commercial experience; selected compact-volume formulations. |
Nasal sprays | Commercial formulations; nasal compatibility, safety and pharmacokinetic performance require product-specific evaluation. |
Topical and scalp | Development opportunity; clinical performance and skin transport not independently validated. |
Swallowed oral | Development opportunity; sublingual observations do not establish GI delivery. |
Liquid-filled capsules | Prospective formulation opportunity, contingent on stability and compatibility. |
Dry powders and stick packs | Prospective format and licensing opportunity; drying feasibility and performance unproven. |
16
3. Intellectual Property and Competitive Position
The Company intends to differentiate through a combination of pending patent applications, proprietary formulation and stabilization methods, confidential technical know-how, manufacturing experience and, ultimately, measurable delivery performance. MODS Max competes for commercial relevance with established liposomal, lipid-based, nasal absorption-enhancement and oral-delivery technologies. These technologies illustrate the quality of evidence that sophisticated partners may require; they do not validate MODS Max by analogy. Freedom-to-operate analyses, patent prosecution and commercial claim scope remain important development considerations.
4. Scientific and Regulatory Validation
Management views a sequenced validation program as important to reducing technical and commercial uncertainty: (i) independent chemical characterization of the input and finished formulations, including relevant reactive constituents and degradation products; (ii) ingredient- and route-specific safety and regulatory assessments; (iii) controlled matched-formulation transport studies; and (iv) pharmacokinetic and other human research where justified and authorized. No performance study should be interpreted as establishing safety or lawful use for other products or routes.
A 2026 retrospective case series involving 15 men using a sublingual enclomiphene formulation incorporating a mineral-oxide system reported an increase in mean testosterone from approximately 347 ng/dL to 805 ng/dL at 60 days and no serious adverse events in the reported group. The study was small, uncontrolled and did not include an enclomiphene-only comparison. It therefore cannot isolate the independent contribution of MODS Max and does not establish the platform’s comparative delivery benefit or comprehensive safety.
The Company is evaluating nasal and peptide-related possibilities, but has not demonstrated injection-equivalent exposure, direct nose-to-brain delivery, or route-wide peptide bioavailability. Product-specific toxicology, analytical methods and applicable regulatory requirements are material prerequisites to any broader pharmaceutical applications.
5. Markets and Product Applications
Current and prospective applications include cellular and NAD-related wellness, mitochondrial-support products, hormone-related formulations, metabolic and GLP-1-adjacent wellness, menopause-related products, selected peptide-related research, skincare and hair/scalp products. Market participation is subject to distinct competitive and regulatory conditions. References to large adjacent pharmaceutical or consumer markets do not establish the Company’s addressable share or the economic value of MODS Max. In particular, potential benefits in weight loss, hormone therapy or peptide administration require product-specific substantiation and appropriate legal pathways.
The Company’s portfolio strategy emphasizes using current formulations to generate product revenue and provide practical development experience while identifying applications in which future technical validation and partner demand may support a separate licensing opportunity.
6. Commercial Strategy — From Owned Products to External Adoption
The current primary economic model is the sale of Company-owned products through direct-to-consumer, wholesale, clinical and other distribution relationships, together with selected co-branded applications. These products may support cash generation, customer learning, manufacturing repeatability and potential partner references.
The longer-term model under evaluation is adoption by unrelated commercial partners. Subject to demonstrated technical usefulness and acceptable commercial terms, this could include technology-access fees, formulation services, input or finished-product supply, field-specific licenses, development milestones and royalties. Licensing is not automatically recurring or high-margin; economics depend on the rights granted, technical support, contractual obligations, partner demand and ongoing costs. No completed arm’s-length third-party MODS Max license has been established in the materials supporting this draft.
Management believes that a paid, independently negotiated third-party technology agreement would represent an important transition: evidence that a business outside BHIC values MODS Max sufficiently to commit commercial resources. The Company’s long-term objective is not simply to sell more products incorporating MODS Max, but to create opportunities to participate economically in products developed, financed and sold by third parties.
7. Valuation Perspective — One Platform, Multiple Potential Revenue Models
Management considers MODS Max a potential multi-application technology asset rather than solely an ingredient supporting individual consumer products. The Company does not believe its value can be established by adding together market-size estimates for all prospective categories, and does not equate prospective opportunities with realized financial value.
A disciplined evaluation would consider incremental operating contribution from existing technology-enabled products, strength of intellectual-property rights, reproducible technical evidence, safety and regulatory feasibility, development costs, partner demand, observed licensing terms, and risk-adjusted future cash flows. Any enterprise valuation must avoid double counting product operating cash flows and related technology benefits.
17
The Company has not obtained an independent appraisal of MODS Max. Capitalized patent costs of $109,845 shown in the working financial notes reflect accounting cost rather than an estimate of the platform’s fair market value; this amount and the applicable reporting period must be reconciled before filing. The Company does not assert a current technology value, valuation multiple or stock-price target in this MD&A.
7.1 Potential value-inflection stages
Current product commercialization | Evidence of formulation, manufacturing and distribution feasibility, but not controlled comparative delivery advantage. |
Independent chemistry, safety and performance studies | May reduce technical and regulatory uncertainty for defined formulations. |
Arm’s-length outside technology agreement | Could provide observable willingness-to-pay and contract-based economic evidence. |
Repeated licensing and contractual royalties | Could establish scalable, recurring economics if commercially successful. |
Validated solid formats and pharmaceutical development | Potential longer-term opportunity requiring additional research, capital and regulatory work. |
8. Priority Development Milestones
Management’s proposed milestones are: independent chemical characterization and route-specific risk assessment; matched active-with/without-MODS Max performance testing; selected nasal and peptide investigations where legally and scientifically appropriate; capsule and dry-format feasibility; pursuit of an initial arm’s-length external licensing or funded-development arrangement; and, only if warranted, exploration of pharmaceutical development partnerships. The sequence, timing and capital requirements will depend on findings, management decisions and available resources. No milestone is assured.
9. Clinical, Technical and Commercial Relationships
Company advisory and commercial relationships have supported product formulation, education and distribution initiatives. Management intends to use qualified independent laboratories and appropriate scientific advisors to build an evidence base suitable for external evaluation. Medical relationships and publications do not substitute for controlled comparative studies. The Company may pursue technology and co-brand relationships subject to verified contractual status, scope, financial terms and regulatory requirements.
10. Operating Infrastructure and Strategic Resource Allocation
The Company has described a deliberate operational transition involving separation from a prior affiliated supply arrangement, supplier qualification, product-portfolio repositioning, development of quality systems, and a NetSuite accounting and inventory upgrade. Management believes these activities are intended to improve scalability, margin visibility, inventory accuracy and public-company readiness. Their financial benefits remain subject to execution and measurable results.
Preparatory activities concerning MODS Max—including intellectual-property work, development of technical documentation, identification of analytical needs and potential partner readiness—have required meaningful management time, energy and operating resources. Management has prioritized this work because it believes a successfully validated and adopted platform could offer a broader set of commercial revenue models than individual branded products alone.
11. Results of Operations — Reconciliation Required
Three Months Ended September 30, 2026 versus 2025
Our net loss for the three months ended September 30, 2026 was $149,225 compared to a net loss of $8,782 during the three months ended September 30, 2025. The Company has generated revenue of $970,071 and $1,131,427 during the three months ended September 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company also had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Expenses incurred were operating expenses of $785,824 during the three months ended September 30, 2026, compared to $707,013 during the three months ended September 30, 2025. Expenses increased as a result of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.
18
Nine Months Ended September 30, 2026 versus 2025
Our net loss for the nine months ended September 30, 2026 was $564,885, compared to a net income $875,720 during the nine months ended September 30, 2025. The Company has generated revenue of $2,757,381 and $4,115,960 during the nine months ended September 30, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales channels and marketing approach due to increased competition and feedback from the marketplace on customer evolving needs and wants. The Company had expected a significant order from a major Co-brand customer, but due to unforeseen events the order was rescheduled to a later date. Operating expenses were $2,378,692 during the nine months ended September 30, 2026, compared to $1,793,134 during the nine months ended September 30, 2025. Expenses increased because of the Company applying to move from the OTC (Over-the-Counter) market to a senior exchange and an increase in marketing and social media to increase and improve our marketing strategy along with an increase in research and development. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.
Management acknowledges that the reported year-over-year revenue decline, once verified, is a material measure of current-period operating performance. Relevant causes include changes in sales and distribution strategies, supplier and operating transitions, the time and resources devoted to technology and infrastructure preparation, and the timing of anticipated distribution opportunities. The Company should quantify each cause to the extent material and supported by its records.
Management further reports that several distribution opportunities originally expected to contribute in 2026 have been delayed, with certain anticipated launches or orders now targeted for 2027. The final filing should distinguish signed arrangements from discussions or nonbinding opportunities and explain material terms and any reasonably known effect on results. Revenue in 2027 is not assured.
12. Liquidity and Capital Resources
As of September 30, 2026, our total assets were $3,204,228, consisting of cash, accounts receivable, income tax receivable, digital assets, inventory, prepaid expenses, right-of-use assets, deposits, and intangible assets. The Company’s net working capital was $2,726,135 and management believes that its cash balance of $1,691,858 as of September 30, 2026 is sufficient to meet its obligations over the next year.
Cash Flows from Operating Activities
We have generated negative cash flows from operating activities. For the nine months ended September 30, 2026, net cash flows used in operating activities was $1,244,807, consisting of our net loss of $564,885 plus changes in operating activities of $679,922. For the nine months ended September 30, 2025, net cash flows providing in operating activities was $272,874, consisting of our net income of $875,720 offset by changes in operating activities of $602,846.
Cash Flows from Investing Activities
For the nine months ended September 30, 2026, we had net cash used in investing activities of $87,420 in connection with the purchase of intangible assets. For the nine months ended September 30, 2025, we had net cash used in investing activities of $46,064 in connection with the purchase of intangible assets.
Cash Flows from Financing Activities
For the nine months ended September 30, 2026, net cash flows provided by financing activities was $2,362,160, consisting of $756,923 in advances from related parties, advances from insurance loan of $42,663 and $2,010,267 of cash acquired for selling common stock, offset by repayments of related party advances of $150,000 and repayment of a related party note payable of $280,000 and repayments to insurance loan of $17,693. For the nine months ended September 30, 2025, net cash flows provided by financing activities was $250,096, consisting of advances from related parties of $2,422,096 offset by repayments to related parties of $2,172,000.
Technology development may require additional spending on analytical testing, independent toxicology, regulatory review, clinical studies, patent prosecution and partner qualification. The Company intends to prioritize development investments based on available financing, findings and commercial relevance. Financing and any associated dilution or debt obligations must be evaluated in connection with the Company’s broader operating needs.
13. Capital Markets and Senior-Exchange Preparation
Management has undertaken initiatives intended to strengthen accounting and inventory systems, governance, shareholder access and potential senior-exchange readiness. The Company has described Regulation A financing activity and engagement of advisors concerning an uplisting. Completion of an exchange listing is subject to applicable requirements and does not assure improved liquidity, a higher trading price or funding availability.
The working filing also describes material weaknesses in disclosure controls and financial reporting controls. Management should align any discussion of operational and institutional readiness with the status of its control-remediation plan and the Company’s actual financial-reporting capability.
19
14. Outlook — Strategic Transformation and Long-Term Shareholder-Value Creation
2026: Building the Foundation for Long-Term Growth
Management views 2026 as an important period of strategic transformation. Although reported revenue has declined year over year, subject to reconciliation of the finalized financial statements, management believes current-period financial performance does not fully describe the Company’s efforts to expand its technological and commercial capabilities. During the period, management deliberately devoted substantial leadership attention and resources to MODS Max, including formulation work, intellectual-property development, technical documentation, supplier qualification, and preparation for potential independent evaluation and strategic partnerships.
These initiatives have competed with resources that otherwise could have been deployed toward near-term sales and distribution activities. Management views this priority as consistent with its objective of creating a business with both ongoing product revenue and potential technology-related revenue streams. The Company cannot establish that this allocation will produce an offsetting financial benefit.
Owned Products and Co-Branded Applications as the First Commercial Foundation
The Company’s own product lines and co-branded applications are important to the MODS Max development story. They demonstrate practical incorporation of the platform into multiple commercial formulations and provide operational evidence regarding product development, manufacturing, selected product stability, distribution and consumer adoption. Management views this experience as the first stage of commercial deployment and as potential reference applications for prospective partners.
This experience should not be confused with independent demonstration of improved absorption or clinical efficacy attributable to MODS Max. Management intends to distinguish operational commercialization from subsequent technical validation and independent economic adoption.
Deliberate Investment in Technology and Institutional Readiness
Management believes preparation of MODS Max for further scientific evaluation and partner review is strategically important. The work has taken significant time, effort and operating resources, in parallel with investments intended to strengthen accounting systems, supplier relationships and public-company infrastructure. Management considers these actions relevant to the Company’s potential senior-exchange objectives, while recognizing that uplisting depends on separate exchange, market, governance and regulatory conditions and is not assured.
Distribution Opportunities Moving Into 2027
Several distribution initiatives that management previously anticipated would generate revenue in 2026 have been delayed, with certain expected commercial launches or orders now anticipated in 2027. Management continues to pursue these opportunities, but future launches, orders and revenue depend on counterparty decisions, executed agreements, product readiness and other conditions. There can be no assurance that the anticipated business will commence in 2027 or generate the revenue originally contemplated.
These timing changes provide context for operating results, but do not eliminate the importance of addressing the current revenue decline or achieving sustainable profitability and positive cash flow.
Three Stages of MODS Max Value Development
Management evaluates progress through three distinct stages: (1) commercial deployment in owned and co-branded products; (2) independent technical validation, including chemical, safety and controlled comparative delivery evidence; and (3) independent economic validation through arm’s-length paying third-party relationships. The Company has experience in the first stage, is developing a program for the second and has not established the third as a recurring revenue model.
Our Long-Term Shareholder-Value Perspective
Management believes the most important potential opportunity is not simply to sell additional products powered by MODS Max. It is to establish MODS Max as an independently validated, commercially adopted delivery technology that unrelated businesses are willing to pay to access, incorporate and license.
If achieved, this transition could allow BHIC to participate in selected products developed, financed, manufactured and sold by other businesses and could provide additional contractual revenue models beyond sales of Company-owned brands. Management believes its 2026 development activities have expanded the potential pathways available for pursuing that objective. This does not establish an increase in fair market value, and the Company has not independently quantified an increase in MODS Max’s value or demonstrated that future opportunities will generate incremental cash flow.
The long-term financial impact remains contingent on technical results, legal and regulatory feasibility, effective intellectual-property protection, partner demand, financing, and operating execution. Management remains focused on improving underlying product performance and advancing the platform through objective validation and commercial milestones.
20
15. Forward-Looking Statements and Material Uncertainties
Statements concerning MODS Max performance, future products and routes, research, distribution launches, strategic partnerships, licensing, future results, platform value, financing and an exchange uplisting are forward-looking and involve uncertainties. Actual outcomes may differ materially. Commercial use, patent-pending status, preliminary human observations and internally prepared strategic analyses do not establish independently verified delivery performance, regulatory authorization, an appraisal of the technology or any future value of the Company’s common stock. The Company’s applicable risk disclosures and finalized financial statements should be considered with this discussion.
OFF-BALANCE SHEET ARRANGEMENTS
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not required.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
As of September 30, 2026 (the “Evaluation Date”), the Company’s management evaluated, with participation of its principal executive officer, the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on that evaluation, the Company’s principal executive officer concluded that the Company’s disclosure controls and procedures were ineffective as of September 30, 2026.
Management assessed the effectiveness of its internal control over financial reporting as of the Evaluation Date based on criteria for effective internal control over financial reporting described in Internal Control—Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. The material weaknesses identified during management’s assessment were (i) a lack of sufficient internal accounting resources; (ii) a lack of segregation of duties to ensure adequate review of financial statement preparation, (iii) lack of an independent board of directors or audit committee, and (iv) lack of written documentation of our internal control policies and procedures. In light of these material weaknesses, management has concluded that we did not maintain effective internal control over financial reporting at the Evaluation Date. We plan to rectify these weaknesses by establishing written policies and procedures for our internal control of financial reporting and hiring additional accounting personnel at such time as we raise sufficient capital to do so. There were no changes in controls during the quarter ended September 30, 2026.
21
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.
Item 1A. Cybersecurity
To date, the Company has not identified any cybersecurity incidents which have materially affected, or are reasonably likely to materially affect, the Company’s business strategy, results of operations or financial condition. The Company has not implemented any specific policies with respect to monitoring and managing cybersecurity threats. Moreover, the Company is aware of the evolution of cybersecurity risks and is taking proactive steps by keeping up to date our information systems and educating our personnel about these risks.
The Company recognizes the importance of developing, implementing, and maintaining cybersecurity measures to safeguard its information systems and protect the confidentiality, integrity, and availability of the data. The Company will be looking to adopt cybersecurity processes, technologies and controls to aid in its efforts to assess, prevent, identify and manage such risks.
Item 2. Unregistered Sales Of Equity Securities and Use Of Proceeds
During the nine months ended September 30, 2026, the Company issued 1,048,159 shares in common stock for cash proceeds of $2,010,267.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Not applicable.
22
Item 6. Exhibits
Exhibit # |
| Exhibit Description |
| Incorporated By Reference |
| Filed or | ||||
|
|
|
| Form |
| Date |
| Number |
|
|
3.1(a) |
|
| S-1 |
| 11/4/2019 |
| 3.1 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
3.1(b) |
|
| 10-K |
| 11/26/2021 |
| 3.1B |
|
| |
|
|
|
|
|
|
|
|
|
|
|
3.2 |
|
| S-1 |
| 11/4/2019 |
| 3.2 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
10.1 |
|
| 10-Q |
| 08/11/2023 |
| 10.1 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
10.2 |
|
| 10-Q |
| 08/11/2023 |
| 10.2 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
10.3 |
|
| 10-Q |
| 08/11/2023 |
| 10.3 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
31.1 |
|
|
|
|
|
|
|
| Filed | |
|
|
|
|
|
|
|
|
|
|
|
31.2 |
|
|
|
|
|
|
|
| Filed | |
|
|
|
|
|
|
|
|
|
|
|
32.1 |
|
|
|
|
|
|
|
| Furnished** | |
|
|
|
|
|
|
|
|
|
|
|
32.2 |
|
|
|
|
|
|
|
| Furnished** | |
|
|
|
|
|
|
|
|
|
|
|
101 |
| Inline Interactive data files pursuant to Rule 405 of Regulation S-T |
|
|
|
|
|
|
| Filed |
|
|
|
|
|
|
|
|
|
|
|
104 |
| Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
|
|
|
|
|
|
|
|
| * | Certain schedules, appendices and exhibits have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule, appendix and/or exhibit will be furnished supplementally to the Staff of the Securities and Exchange Commission upon request. |
| ** | This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K. |
23
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioScience Health Innovations Inc. | |
|
|
|
Dated: November 13, 2026 | By: | /s/ Darren Lopez |
|
| Darren Lopez |
|
| Chief Executive Officer |
|
| (Principal Executive Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Name |
| Title |
| Date |
|
|
|
|
|
/s/ Darren Lopez |
| Principal Executive Officer and Director |
| November 13, 2026 |
Darren Lopez |
|
|
|
|
24